Atai Life Sciences, a Peter Thiel-backed company that produces psychedelic and non-psychedelic mushroom-based therapies for depression and anxiety, is expected to go public. We'll update this page as new information emerges.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $1.58 |
|---|---|
| 52-week range | $1.03 - $2.85 |
| 50-day moving average | $1.49 |
| 200-day moving average | $1.62 |
| Wall St. target price | $10.68 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.21 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.58 from 2024-07-25
| 1 week (2024-07-19) | 6.76% |
|---|---|
| 1 month (2024-06-27) | 19.70% |
| 3 months (2024-04-26) | -18.13% |
| 6 months (2024-01-26) | -8.14% |
| 1 year (2023-07-27) | -22.55% |
|---|---|
| 2 years (2022-07-25) | -58.20% |
| 3 years (2021-07-27) | 16.29 |
| 5 years (2019-07-23) | N/A |
| Revenue TTM | $277,000 |
|---|---|
| Gross profit TTM | $233,000 |
| Return on assets TTM | -26.02% |
| Return on equity TTM | -15.92% |
| Profit margin | 0% |
| Book value | $1.34 |
| Market Capitalization | $247.8 million |
TTM: trailing 12 months
We're not expecting ATAI Life Sciences to pay a dividend over the next 12 months.
Over the last 12 months, ATAI Life Sciences's shares have ranged in value from as little as $1.025 up to $2.85. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ATAI Life Sciences's is 0.8. This would suggest that ATAI Life Sciences's shares are less volatile than average (for this exchange).
To put ATAI Life Sciences's beta into context you can compare it against those of similar companies.
Atai Life Sciences N. V. , a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression.
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
Learn the basics of put options: what they are, how they work and a few examples.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out our 7 ideas for how to invest $10K to maximize your money.
Check out the best-performing ETFs so far in 2024.